{'52WeekChange': -0.03999996,
 'SandP52WeekChange': 0.0644362,
 'address1': '1330 Avenue of the Americas',
 'address2': '33rd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.88,
 'askSize': 1800,
 'averageDailyVolume10Day': 686050,
 'averageVolume': 1058847,
 'averageVolume10days': 686050,
 'beta': 1.522128,
 'beta3Year': None,
 'bid': 2.85,
 'bidSize': 4000,
 'bookValue': 1.583,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.94,
 'dayLow': 2.8299,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.039,
 'enterpriseToRevenue': None,
 'enterpriseValue': 132723032,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.9888573,
 'fiftyTwoWeekHigh': 5.19,
 'fiftyTwoWeekLow': 1.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 69604034,
 'forwardEps': -0.8,
 'forwardPE': -3.6000001,
 'fromCurrency': None,
 'fullTimeEmployees': 88,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.17819001,
 'heldPercentInstitutions': 0.66402,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1414108800,
 'lastSplitFactor': '1:50',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/abeonatherapeutics.com',
 'longBusinessSummary': 'Abeona Therapeutics Inc., a clinical-stage '
                        'biopharmaceutical company, develops gene and cell '
                        'therapies for life-threatening rare genetic diseases. '
                        'Its lead programs include EB-101, an autologous, '
                        'gene-corrected cell therapy for recessive dystrophic '
                        'epidermolysis bullosa; ABO-102, an adeno-associated '
                        'virus-based gene therapy for Sanfilippo syndrome type '
                        'A; and ABO-101, an AAV-based gene therapy for '
                        'Sanfilippo syndrome type B. The company also develops '
                        'ABO-202 and ABO-201, which are AAV-based gene '
                        'therapies for the CLN1 and CLN3 forms of Batten '
                        'disease; ABO-401 for the treatment of cystic '
                        'fibrosis; and ABO-5OX for the treatment of genetic '
                        'eye disorders. In addition, it is developing '
                        'AAV-based gene therapy through its AIM vector '
                        'platform programs. Abeona Therapeutics Inc. has a '
                        'license agreement with REGENXBIO Inc. for the '
                        'development and commercialization of gene therapies '
                        'for the treatment of MPS IIIA, MPS IIIB, CLN1 '
                        'disease, and CLN3 disease. The company was formerly '
                        'known as PlasmaTech Biopharmaceuticals, Inc. and '
                        'changed its name to Abeona Therapeutics Inc. in June '
                        '2015. Abeona Therapeutics Inc. was incorporated in '
                        '1974 and is headquartered in New York, New York.',
 'longName': 'Abeona Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 241049968,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_360935',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -105886000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646-813-4712',
 'previousClose': 2.95,
 'priceHint': 4,
 'priceToBook': 1.8193306,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.94,
 'regularMarketDayLow': 2.8299,
 'regularMarketOpen': 2.93,
 'regularMarketPreviousClose': 2.95,
 'regularMarketPrice': 2.93,
 'regularMarketVolume': 341962,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 83622096,
 'sharesPercentSharesOut': 0.0363,
 'sharesShort': 3037299,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2167650,
 'shortName': 'Abeona Therapeutics Inc.',
 'shortPercentOfFloat': 0.0438,
 'shortRatio': 3.17,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'ABEO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.721,
 'twoHundredDayAverage': 2.751151,
 'volume': 341962,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.abeonatherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10019'}